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Introduction
Community-Acquired Pneumonia (CAP) is the most common cause 
of mortality caused by infectious disease in developed countries. Over 
the last few years, hospital emergency rooms (HER) have been using se-
verity prognostic scales (predictive scales) that help determine the need 
for hospitalization. The two most robust, often used, and validated clin-
ical severity scales are PSI and CURB-65 (1, 2). However, these severity 
indexes have limitations, as shown by the fact that up to 16% of patients 
admitted to the ICU for CAP belong to PSI risk groups I–III (3).
Over the last few years, Brain Natriuretic Peptide (BNP) has been 
investigated as a prognosis marker for CAP in emergency rooms, 
internal medicine, and intensive care units (4-9). Of these studies, few 
have compared the predictive capacity between biomarkers, and 
none have compared NT-ProBNP with one of the infectious markers 
most often used in the HER, procalcitonin (PCT). There are no studies 
on the capacity of NT-ProBNP to detect severe CAP when associated 
with other biomarkers.
As there is an established relationship between pneumonia 
and cardiovascular events and NT-ProBNP is a biomarker for cardiac 
stress, the purpose of our study was to 1) evaluate the relationship 
between the plasma concentration of NT-ProBNP at the time of di-
agnosis of CAP in the emergency room with the severity of CAP, de-
fined as mortality at 30 days; 2) compare the prognostic capacity of 
NT-ProBNP with predictive scales and biomarkers normally used in 
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Abstract
Aim: Community-acquired pneumonia (CAP) is an infectious disease that causes the highest mortality rates in developed countries. The primary endpoint of 
this study was to evaluate the relationship between the plasma concentration of the amino-terminal fragment of pro-brain natriuretic peptide (NT-ProBNP) at 
the time of CAP diagnosis in a hospital emergency room (HER) and its severity, determined as mortality at 30 days.
Materials and Methods: A prospective, observational cohort study was used to determine NT-ProBNP (ng/L) in patients with CAP, with a follow-up over 30 
days and analysis of the mortality rate.  
Results: A total of 338 patients were assessed. Thirty patients died within the first 30 days (10.5%). The mean NT-ProBNP values in the deceased patients were 
14,035 ng/L (SD: 19,271) compared to 1,711 ng/L (SD: 3,835) in survivors (p<0.0001). The cut-off point of 1,769 ng/L showed a negative predictive value (NPV) 
of 95.3%, whereas 10,808 ng/L showed a positive predictive value (PPV) of 73.3%. The diagnostic performance of NT-ProBNP reached an AUC of 0.783 (95% 
CI: 0.731–0.829). Entering the potential confounding variables in a logistic regression model revealed that NT-ProBNP behaved like an independent risk factor. 
Grouping the NT-ProBNP values by every 300, 500, 1,000, and 2,000 ng/L increased the risk of mortality at 30 days by 3%, 5.1%, 10.5%, and 22%, respectively.
Conclusion: The NT-ProBNP values at the time of CAP diagnosis are significantly higher among patients that die than those that survive the first 30 days, and it 
could be a good predictor of early mortality. NT-ProBNP has good overall accuracy and behaves like an independent risk factor. (Eurasian J Emerg Med 2016; 15: 30-8)
Keywords: Amino-terminal fragment of pro-brain natriuretic peptide (NT-ProBNP), community-acquired pneumonia, emergency room, mortality, biomark-
ers, severity prognostic scales
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the emergency room; 3) study the strength of association between 
NT-ProBNP and severity prognostic scales and biomarkers normally 
used in the emergency room; 4) evaluate whether the association of 
NT-ProBNP with predictive scales and biomarkers results in improved 
predictions; 5) analyze the increased risk of mortality from CAP with 




A prospective, longitudinal cohort trial was designed with the 
inclusion of subjects between February 2012 and 2013 with a clinical 
diagnosis of pneumonia and radiographic confirmation. Consider-
ation is given to CAP if the process takes place for a patient who has 
not been hospitalized during the last 14 days; in the event that the 
patient was already in hospital, it was diagnosed within the first 48 h 
of the hospital stay. 
The inclusion criteria were that the patient must be over 14 years 
of age and comply with the definition of pneumonia and CAP. The 
predictor variable was considered to be the result of the determi-
nation of NT-ProBNP in blood (in ng/L); the dependent variable was 
mortality at 30 days.
The case report form should be completed by at least two emer-
gency room physicians. A specialist in radiodiagnosis made a blind 
a posterior examination of each of the x-rays as he had no clinical 
knowledge of the patients. A contact interview took place at one 
month, either in person, by phone, or through the electronic clinical 
record depending on the patient’s final destination, to determine the 
patient’s progress.
This study was designed in accordance with the ethical princi-
ples of the Declaration of Helsinki. The study protocol was approved 
by the Institutional Review Board of our region, Cantabria (IEC/IRB 
act 8/2012), as well as by the training commission of Laredo Hospi-
tal, a public hospital in the north of Spain covering a population of 
95,000 people.
Data collection
The following baseline data was obtained from the patients: 
demographic (age and sex), comorbidity, personal history (alcohol 
and tobacco use and body mass index), physical examination (heart 
and respiratory rate, pulsoximetry, and systolic and diastolic blood 
pressure), laboratory tests (leukocytes, neutrophils, hematocrit, hae-
moglobin, platelets, glucose, urea, creatinine, sodium, bilirubin, pro-
thrombin time, activated partial thromboplastin time, arterial oxy-
gen and carbon dioxide partial pressure, arterial pH), chest X-ray, and 
biomarkers (C-reactive protein (CRP), procalcitonin (PCT), lactate, 
D-dimer (D-D), high-sensitivity troponin T, and NT-ProBNP). The se-
verity of the CAP was assessed using severity prognostic scales (PSI, 
CURB-65, and ATS/IDSA). 
Blood samples
Blood samples were obtained on arrival of the patient in the 
emergency room. The physicians responsible for the patient request-
ed NT-ProBNP and all determinations considered necessary for cor-
rect care of the patient. 
Determinations of NT-ProBNP and other biomarkers 
The NT-ProBNP sample was collected in a biochemistry tube 
and analyzed using the proBNP II-Elecsys 2010 kit (Roche Diagnos-
tics GMBH, SandhoferStrasse 116, D-68305 Mannheim, Germany). 
The analytical technique used was an electrochemiluminescence im-
munoassay (ECLIA) using the sandwich principle. The measurement 
range of the assay was between 5 and 35,000 ng/L; however, mea-
surements of up to 70,000 ng/L could be performed using appropri-
ate dilutions.
Statistical analysis
For statistical analysis, categorical variables were described as 
absolute value and percentage, and continuous variables were de-
scribed by their means, standard deviations, and 95% confidence 
intervals (95% CI) and/or medians and interquartile ranges. The anal-
yses were performed using the SPSS Statistics Package for Windows 
(version 20.0) and MedCalc (version 11.7). 
A comparison was made for each variable between the surviv-
ing and non-surviving groups. The assessment of differences be-
tween the NT-ProBNP concentrations of patients with CAP, survivors, 
and non-survivors with different biomarkers and SPS as quantitative 
variables was performed by bivariate analysis using Student’s t-test if 
they followed a normal distribution or the Mann–Whitney non-para-
metric U test if not. The type of distribution for quantitative variables 
was first checked using the Kolmogorov–Smirnov Z test. The differ-
ences between groups for qualitative variables were evaluated using 
the Chi-square or Fisher’s test. 
NT-ProBNP was analysed as a predictor of mortality by calcu-
lating the ideal cutoff point optimised by multiplying sensitivity by 
specificity using mortality at 30 days as a reference and plotting the 
receiver operating characteristic (ROC) curve. The strength of the re-
lationship between numerical variables was evaluated using Spear-
man’s non-parametric coefficient of correlation test. 
Survival was analysed using the Kaplan–Meier method, compar-
ing curves by the Log-Rank test. Logistic regression analysis and the 
Enter method were then applied to estimate whether the variable of 
interest, NT-ProBNP, provided any additional predictive improvement 
to consolidated predictive scales. The personal history of ischaemic 
cardiopathy, heart and kidney failure, and age were included as cat-
egorical confusion variables. Multivariate analysis using NT-ProBNP 
as a dichotomous variable according to the cutoff point was used to 
calculate the raw risk after including the confounders in the mod-
el. The prediction models were compared using the Hosmer–Leme-
show test.
Results
General characteristics of the patients with pneumonia in
cluded to the study
A total of 338 patients were assessed, 287 being included in the 
study (84.9%). In total, 2% of the rejected patients had nasocomial pneu-
monias, 8% were pediatric patients, 20% had no request for NT-ProBNP, 
22% had a final diagnosis other than CAP, and 48% were rejected by the 
radiologist as they had no clear radiological condensation. 
Overall, 42.2% of patients included in the study were women. The 
mean age was 66±21 years (min. 14, max. 104). The main demographic 
characteristics, comorbidity, clinical and radiological variables, prognos-
tic scales, and biomarkers for each group are shown in Tables 1 and 2.
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                          Survivors  n=257                         Death   n=30    
Personal characteristics Mean SD Med IQR Mean SD Med IQR p
Age 64.1 21.3 67.0 37.0 82.9 14.2 86.0 11.0 <0.001
BMI 25.9 5.5 25.0 7.0 22.9 3.9 23.0 5.0 0.163
Alcohol C. g/week 21.9 62.6 0 0 36.8 130.7 0 0 0.450
Smoker cigarette/day 4.6 9.7 0 2.0 0 0 0 0 0.014
Vital Signs         
HR, bpm 97.5 19.4 97 27.8 97.2 21.9 95 24.0 0.957
RR, rr 20.2 6.0 20.0 8.0 31.1 7.8 30.0 13.3 <0.001
SBP, mm Hg 132.3 24.5 132.0 32.8 119.2 26.1 115.0 34.0 0.004
DBP, mmHg 72.1 12.7 72.0 17.0 60.8 13.0 61.0 20.0 <0.001
Body temperature, ºC 37.7 1.1 37.8 1.7 37.3 1.2 37.2  1.5 0.046
Blood oxygen level, % 93.7 4.4 95.0 6.0 86.1 9.1 88.0 14.3 <0.001
Laboratory values         
Leukocytes per, mm3 12027 5586 11100 6800 14703 9065 13050 12300 0.158
Neutrophils per, mm3 9876 5398 8900 6350 12713 8082 10950 11375 0.072
Haematocrit, % 39.5 5.1 40.0 6.0 36.0 7.9 36.5 10.3 0.008
Haemoglobin, g/dL 13.2 2.5 13.1 2.1 11.7 2.5 11.5 3.5 <0.001
Platelets per, 1000/mm3 231 89 220 103 277 159 240 171 0.209
Glucose, mg/dL 146 78 124 52 175 70 159 103 0.005
Urea, mg/dL 45.6 30.8 39.0 24.5 106.5 85.6 78.5 54.3 <00001
Creatinine, mg/dL 1.0 0.5 0.9 0.4 2.0 2.6 1.3 0.9 0.005
Sodium, mEq/L 136 5.8 136 5.0 138 9.7 136 9.5 0.483
Bilirubin, mg/dL 0.53 0.29 0.50 0.30 0.64 0.54 0.50 0.30 0.253
Prothrombin time, % 74.9 23.1 81.0 23.3 70.3 17.0 69.0 20.5 0.021
APTT sec. 35.8 3.9 35.5 7.8 33.4 3.3 32.8 6.3 0.480
PO2 mmHg 63.3 14.7 61.0 15.0 51.5 14.2 50.0 23.0 <0.001
pCO2 mmHg 37.4 6.6 37.0 8.0 41.1 18.1 34.5 18.3 0.518
Arterial, pH 7.47 0.06 7.46 0.06 7.40 0.13 7.45 0.19 0.047
GFR est. mL/min/1.73 m2 86.2 34.4 85.4 41.8 73.2 61.3 47.7 55.9 0.049
Biomarkers         
CRP, mg/dL 13.6 13.7 8.9 17.1 16.1 16.4 11.6 17.2 0.333 
PCT, ng/mL 1.6 5.6 0.2 0.5 4.8 100 0.4 2.8 0.007
Lactate, mg/dL 14.3 8.4 13.0 10.0 30.6 11.4 36.0 23.8 0.058
D-Dimer, mcg/mL 2.3 2.0 1.9 2.2 4.3 2.2 5.1 4.2 0.082
Troponin T high sensitive, ng/L 58.1 198 11.0 27.0 214.4 321.6 95.0 248 <0.001
NT-ProBNP, ng/L 1711 3835 411 13400 14035 19271 5192 1968 <0.001
Prognostic scales         
PSI 77.4 36.5 78.0 57.5 137.2 38.1 137.2 50.0 <0.001
CURB-65 1.06 1.07 1.0 2.0 3.0 1.2 3.0 2.0 <0.001
ATS/IDSA major criteria 0 0.06 0.0 0.0 0.17 0.46 0 0 <0.001
ATS/IDSA minor criteria 0.77 1.05 0.0 1.0 2.97 1.27 3.0 2.0 <0.001
Progress         
Length of stay 8.7 5.2 7.0 5.0 ------ ----- ------- ------ ------
Days to death ------ ------ ------ ------ 7.5 6.4 5.5 6.7 ------
Med: median; IQR: inter-quartile range; Alcohol C: alcohol use consumption; Smoker: tobacco use HR: heart rate; RR: respiratory rate; BMI: body mass index; bpm: beats 
per minute; rr: respiratory rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; ºC: degrees centigrade; GFR: glomerular filtration rate; APTT: activated partial 
thromboplastin time; CRP: C-reactive protein; PCT: procalcitonin; ATS/IDSA: American Thoracic Society/Infectious Diseases Society of America; PSI: pneumonia severity 
index; CURB-65: acronym for Confusion; BUN: Blood Urea Nitrogen, Respiratory rate, Blood pressure, age over 65 years
Table 1. General characteristics of the sample. Comparison between survivors and deaths in the first 30 days
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Description of the outcome predictor variable
The results interval found was between 8 and 70,000 ng/L, with 
an arithmetic mean of 3,000 ng/L (SD 8,068 ng/L) and a median of 
492 ng/L (IQR: 138–2.003). The values for survivors and death are 
shown in Figure 1. 
There were statistically significant differences between the sur-
viving and deceased patients at 30 days (median 5,192 ng/L; IQR 
19,685 vs. median 411; IQR 1,340 ng/L, p<0.001).
Prognostic capacity of NT-ProBNP in CAP
The cutoff points were calculated depending on the mortality 
at 30 days. The cutoff point was 1,769 ng/L to optimize sensitivity 
(66.7%; 95% CI: 47.2–82.7), specificity (78.2%; 95% CI: 72.7–83.1), 
positive predictive value (PPV, 26.3%), and negative predictive value 
(NPV, 95.3%). For a cutoff point of 232 ng/L, the sensitivity was 93.3% 
(95% CI: 77.9–99.2), specificity was 39.3% (95% CI: 33.3–45.6), PPV 
was 15.2%, and NPV was 98.1%. For a cutoff point of 10,808 ng/L, the 
sensitivity was 36.7% (95% CI: 19.9–56.1), specificity was 98.4% (95% 
CI: 96.1–99.6), PPV was 73.3%, and NPV was 93% (Figure 2). 
When proposing mixed models with demographic variables 
(age), predictive scales (PSI, CURB-65 and ATS/IDSA 2007), and bio-
markers (CRP, PCT, and NT-ProBNP), the most advantageous model 
combines ATS/IDSA with PCT and NT-ProBNP with an AUC of 0.94.
The diagnostic performance of NT-ProBNP, some other markers 
such as procalcitonin, and diverse scoring systems used for pneumo-
nia are depicted in Table 3. 
Correlation between NT-ProBNP and predictive scales 
A study was made of the correlation between NT-ProBNP and 
the PSI, CURB-65 predictive scales, and minor ATS/IDSA criteria. There 
was a good association between NT-ProBNP and the PSI scales (Rho 
0.71 p=0.0001) and CURB-65 (Rho 0.65 p=0.0001) and a slight associ-
ation with the ATS/IDSA minor criteria (Rho 0.48 p=0.0001). 
Logistic regression model
a. NT-ProBNP as an independent risk factor for early mortality
Initially, a univariate analysis was performed depending on 
mortality for the following variables as dichotomous variables: age, 
background of heart failure, ischaemic cardiomyopathy and chronic 
kidney failure, serum creatinine, NT-ProBNP, PSI score, CURB-65 score, 
minor ATS/IDSA criteria score, and ATS/IDSA scale. The variables with 
p<0.25 (age, ischaemic cardiomyopathy, creatinine, NT-ProBNP, PSI, 
CURB-65, minor ATS/IDSA criteria, and ATS/IDSA as dichotomous 
variables) were entered into a logistic regression model. Furthermore, 
forced multivariate analysis was performed on the personal history 
of heart failure and chronic kidney failure, as these variables have an 
established relationship with NT-ProBNP levels and therefore could 
be confusion factors. After adjustment for all these variables, the only 
ones that maintained statistical significance were age (p=0.002), ATS/
IDSA 2007 (p=0.001), and NT-ProBNP (p=0.001).
b. Assess improved outcome prediction by associating 
NT-ProBNP and other biomarkers 
A univariate analysis of NT-ProBNP and the CRP and PCT bio-
markers revealed that only PCT (p=0.043) and NT-ProBNP (p<0.0001) 
showed significant differences between patients that died and sur-
vived at 30 days.
Table 2. General characteristics of the sample. Comparison between 
survivors and deaths in the first 30 days
                 Survivors          Death
 No % No % p
Total 257 89.5 30 10.4 
Sex             
   Female 106 41.2 15 50 0.358
   Male 151 58.8 15 50  
Comorbidity   
   Heart failure 20 7.8 3 10 0.719
   Ischemic cardiopathy 19 7.4 5 16.7 0.089
   Chronic kidney failure 13 5.1 3 10 0.227
   Chronic respiratory disease 52 20.2 1 3.3 0.024
   Essential HBP 101 39.3 19 6.3 0.012
   DM-1 0 0 1 3.3 0.105
   DM-2 47 18.3 8 26.7 0.270
   Chronic hepatopathy 7 2.7 1 3.3 0.519
   Cerebral vascular disease 12 4.7 6 20 0.006
   Severe psychiatric disorder 5 1.9 0 0 1.000
   Dementia 20 7.8 13 43.3 <0.001
   Malignancy 19 7.4 4 13.3 0.279
   Immunosuppression 2 0.8 0 0 1.000
   Disorder preventing oral 1 0.4 0 0 0.732
   treatment  
   Construction work at home 6 2.3 0 0 0.398
   or workplace
   Cohabitation with animals  33 12.8 4 13.3 0.939
Risk Groups    
   ATS/IDSA 19 7.4 21 70 <0.001
   PSI 257  30  <0.001
      I 73 28.4 0 0 
      II 40 15.6 0 0
      III 58 22.6 4 13.3
      IV 66 25.7 10 33.3
      V 20 7.8 16 53.3
   CURB-65 257  30  <0.001
       1 180 70 3 10
       2 52 20.2 8 26.7
       3 25 9.7 19 63.3
HER: hospital emergency room; HBP: high blood pressure; DM-1: diabetes mellitus type 
1; DM-2: diabetes mellitus type 2; ATS/IDSA: American Thoracic Society/Infectious Disea-
ses Society of America; PSI: pneumonia severity index; CURB-65: acronym for Confusion, 
BUN: Blood Urea Nitrogen, Respiratory rate, Blood pressure, age over 65 years
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Survival analysis 
It was observed that 20% of patients died within the first 48 hrs 
and 50% within the first 5 days. Comparison of the survival curves de-
pending on the cutoff point showed significant differences between 
the patients that died for values over 1,769 ng/L [(hazard ratio 6.2 (CI 
2.9-13.2, p=0.0001)], as can be seen in Figure 3.
The survival curves were also compared depending on sex, back-
ground of heart failure, ischaemic cardiomyopathy and chronic kid-
ney failure, and creatinine serum levels above and below 1.2 mg/dL. 
The only significant differences were found for the latter variable 
(p<0.001).
Discussion
The World Health Organisation estimates that infections of the 
lower airways are the most common cause of death by infectious 
disease in the world, with close to 3.5 million deaths a year (10). Ear-
ly assessment of the severity of pneumonia is crucial to the correct 
management of these patients. Over the last few years, a multitude 
Figure 1. NT-ProBNP values on a scale of 0–20,000 ng/L (left) and on a scale of 0–70,000 ng/L (right)











































CRP + NT-ProBNP 0.79 
PCT + NT-ProBNP 0.85
CRP + PCT + NT-ProBNP 0.82
PSI + NT-ProBNP 0.90
CURB65 + NT-ProBNP 0.91
ATS/IDSA + NT-ProBNP 0.93
PCT + ATS/IDSA + NT-ProBNP 0.94
Age + PCT + NT-ProBNP 0.86
Age + PCT + ATS/IDSA + NT-ProBNP 0.95
ROC: receiver operating characteristic; PCT: procalcitonin; CRP: C-reactive prote-
in; ATS/IDSA: American Thorax Society/Infectious Diseases Society of America; 
CURB-65: acronym for Confusion, BUN: Blood Urea Nitrogen, Respiratory rate, 
Blood pressure, age over 65 years
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of clinical tools have been designed and developed to predict mortali-
ty and help decide the care site, with PSI and CURB-65 being the most 
reliable and most often used in the HER (1-2). However, these scales are 
quite often not applied, either because they are simply not used or be-
cause objective data such as low blood oxygen level or subjective data 
such as poor family support recommend admission of the patient (11).
Biological markers and their role in the inflammatory response and 
relationship to the severity of pneumonia are undering study. Biomark-
ers may be an alternative to assess the seriousness of pneumonia and 
predict mortality. These biomarkers include natriuretic peptides (NP) 
(12-14). The first team to assess NT-ProBNP as a predictor of early mortal-
ity at 30 days were Jeong et al. (4), who in 2011 conducted a retrospec-
tive study of hospitalized patients, obtaining promising results in their 
series of 167 patients. According to our information, this NP was recently 
studied as a prognosis marker for CAP in different scenarios: emergency 
room (5, 9), hospitalized patients (6), and intensive care units (7, 8).
Description of the outcome predictor variable
We found large differences between NT-proBNP values in survi-
vors and deaths within the first 30 days; there were statistically signif-
icant differences between both groups, as in other studies conduct-
ed to date.
Prognostic capacity of NT-ProBNP in CAP
The ideal cutoff point balancing sensitivity and specificity found 
in our study was 1,769 ng/L. This result is in line with that of stud-
ies by Jeong (1,795.5 pg/mL), Nowak (1,935 ng/L), and Chang (1,860 
ng/L) in patients diagnosed in the Emergency Room and admitted 
to a conventional hospital ward (4-6). Our cutoff point differs from 
that of the cohort by Lin et al. (7) (2,177.5 ng/L). Their patients had 
more severe CAP, with 83% of patients meeting ATS/IDSA criteria 
compared to 14% in our series. They also evaluated other types of 
pneumonia, including hospital-acquired (25%) and that associated 
with social and health care (40%). We also found differences with the 
cutoff point established by Xiao et al. (8), almost certainly because 
this group reduced the cutoff point to obtain a sensitivity of 98.7%.
As severe CAP is a dangerous, but treatable, disease whose se-
verity should be assessed as soon as possible, lowering the cutoff 
point to 232 ng/L would provide a sensitivity of 93.3% (95% CI: 0.78–
0.99), higher than 90% (95% CI: 0.87–0.92), in reference to the Fine’s 
score in the above meta-analysis. This could therefore be useful in the 
HER to identify patients with non-severe pneumonia and low risk of 
death who could be safely discharged. Our sensitivity is very close to 
those of the studies by Jeong and Nowak when they dropped their 
cutoff points to 235.6 ng/L and 628 ng/L, respectively (4, 5).
A higher cutoff point (10,808 ng/L) would indicate patients re-
quiring a more aggressive initial treatment. 
Assessment of the diagnostic performance of NT-ProBNP
After studying the general accuracy of the diagnostic test using 
ROC curves, NT-ProBNP has good capacity as a diagnostic test to pre-
dict mortality at 30 days, with an AUC of 78%. The studies performed 
to date found an AUC of between 71% and 88% (Table 4).
Comparison of the prognostic capacity of NT-ProBNP compared 
to a scale to predict severity 
The accuracy of these two prediction scales has been compared 
in various reviews and meta-analyses, resulting in a high NPV in popu-
lations with a low prevalence of death, a PSI sensitivity of about 90%, 
a CURB-65 specificity of close to 80%, and suitable diagnostic capacity 
with an AUC of around 80% (15-17). However, in spite of the value of 
these tools, approximately 30%–60% of low risk CAP patients are hos-
pitalized, there being considerable disagreement between the recom-
























Studies                              NT-ProBNP                          PSI                           CURB-65                               ATS/IDSA
 AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
Jeong et al. (4) 0.71 0.61–0.81 0.80 0.74–0.85 0.76 0.70–0.83 - -
Nowak et al. (5) 0.73 0.67–0.77 0.76 0.71–0.81 0.65 0.61–0.70 - -
Chang et al. (6) 0.88 0.82–0.94 0.87 0.83–0.91 - - - -
Lin et al. (7) 0.72 0.65–0.78 - - - - 0.65 0.58–0.63
Xiao et al. (8) 0.77 0.71–0.84 0.87 0.82–0.92 0.81 0.75–0.87  
Tazón Varela et al. (9) 0.78 0.73–0.83 0.88 0.83–0.91 0.87 0.83–0.91 0.89 0.85–0.92
SPS: Severity Prognostic Scale
Table 4. Assessment of the predictive capacity of NT-ProBNP and SPS for mortality at 30 days
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In our sample, the two scales to predict severity showed better 
diagnostic performance than the biomarker. Nevertheless, the AUC 
obtained in our study for the predictive scales was at the same height 
of the upper range of the AUC found in systematic reviews and me-
ta-analyses (16, 17). We therefore understand that the diagnostic ca-
pacity of NT-ProBNP could be useful in the same terms as the use of 
PSI and CURB-65 scales.
Comparison of the prognostic capacity of NT-ProBNP compared 
to other biomarkers
Over the last few years, medical literature has accepted the useful-
ness of PCT to differentiate acute systemic bacterial infections in CAP 
to assess the response to treatment or predict hospitalization (19, 20). 
However, there is still controversy regarding its capacity to predict ear-
ly mortality. Some studies, such as those by Krüger et al. (21), Horie et 
al. (22), or Park et al. (23), attribute good capacity to PCT. However, in a 
systematic review of 30 publications, the ability of PCT to predict early 
mortality was found to be very similar to our results (24). In our sam-
ple, the association of NT-ProBNP with PCT, a combination not used to 
date, provided high specificity (98%) to detect severe CAP. This combi-
nation of infectious and cardiovascular stress biological markers could 
be useful in the HER or ICU to detect potentially severe patients. 
Among the studies that analyze NT-ProBNP and its relationship 
to CAP, there are very few that study and compare other biomarkers. 
Only Jeong et al. (4) and Nowak et al. (5) assessed infectious-inflam-
matory biological markers (leukocytes and CRP); they obtained re-
sults very similar to ours, attributing a low predictive capacity to both 
variables (Table 5).
Correlation between NT-ProBNP and predictive scales 
A study was made of the association between NT-ProBNP and 
predictive scales such as quantitative variables. There was positive 
and significant interdependence between the severity of pneumonia 
and the PSI and CURB-65 scales and minor ATS/IDSA 2007 criteria, 
the strongest association being with Fine’s score (Rho 0.71 p<0.0001). 
These findings are in agreement with Nowak et al. (5), who also found 
a significant interrelationship between early mortality and the PSI 
scale (Rho 0.53 p<0.001).
Correlation between NT-ProBNP and other biomarkers
A study was made of the strength of the association between 
NT-ProBNP and the analyzed biomarkers. Except for troponin T, the 
correlation was weak with the other inflammatory markers normally 
used in an emergency room, such as leukocytes (Rho 0.14 p=0.02), CRP 
(Rho 0.18 p=0.003), and PCT (Rho 0.33 p=0.001). Of special note is the 
low interrelationship between NT-ProBNP and CRP. Nowak et al. (5) also 
did not find any correlation between NT-ProBNP, leukocytes, and CRP.
Logistic regression model
a. NT-ProBNP as an independent risk factor for early mortality
A logistic regression analysis was performed, adjusting for pos-
sible confusing factors. Only age, the ATS/IDSA scale, and NT-ProBNP 
maintained statistical significance. However, NT-ProBNP was the only 
factor maintaining statistical significance in all models. Therefore, 
age, meeting ATS/IDSA 2007 criteria, and high NT-ProBNP levels are 
independent predictors of early mortality. These results are consis-
tent with the literature, where NT-ProBNP is also highlighted as an 
independent risk factor (4-6).
From the evolutionary point of view, an increase of 1 ng/L is 
not relevant for the clinician; therefore, we grouped the increases of 
NT-ProBNP as 300, 500, 1,000 and 2,000 ng/L, noting that the risk of 
death with the first 30 days increased from 3% to 22%. Future studies 
will be required to determine the solidity of these results and wheth-
er this biomarker could be a useful tool in HER and observation units 
to determine the progress of patients with CAP.
Study                              NT-ProBNP                                  Leukocytes                                Neutrophils                        D-Dimer
 AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
Jeong et al. (4) 0.71 0.61–0.81 - - - - - -
Nowak et al. (5) 0.73 0.67–0.77 0.52 0.42–0.61 - - - -
Chang et al. (6) 0.88 0.82–0.94 - - - - - -
Lin et al. (7) 0.72 0.65–0.78 - - - - - -
Xiao et al. (8) 0.77 0.71–0.84 - - - - - -
Tazón Varela et al. (9) 0.78 0.73–0.83 0.58 0.51–0.64 0.60 0.54–0.66 0.75 0.56–0.88
Study                          CRP                                PCT                          Lactate                             Troponin T
 AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
Jeong et al. (4) - - - - - - - -
Nowak et al. (5) 0.55 0.46–0.64 - - - - - -
Chang et al. (6) - - - - - - 0.79 0.71–0.87
Lin et al. (7) - - - - - - - -
Xiao et al. (8) - - - - - - - -
Tazón-Varela et al. (9) 0.56 0.49–0.62 0.66 0.60–0.72 0.80 0.60–0.93 0.85 0.72–0.93
AUC: area under the curve; CI: confidence interval; CRP: C reactive protein; PCT: Procal citonin
Table 5. Assessment of the predictive capacity of NT-ProBNP and biomarkers for mortality at 30 days
Eurasian J Emerg Med 2016; 15: 30-8
Tazón-Varela et al.
Natriuretic Peptide Predicting Mortality in Pneumonia36
b. Assess improved prediction of outcome by associating 
NT-ProBNP and predictive scales
Some studies are headed in the direction of adding a biomarker 
to predictive scales to improve the predictive capacity for mortality 
and the absence of severe complications (25, 26). Several biochemical 
markers improve the prediction of mortality at 30 days for predictive 
scales in hospitalized patients, including vitamin D status with PSI (27), 
CRP with PSI, CURB-65 and CRB-65 (28), CRP and PCT with CURB-65 
(29), cortisol with CRB-65 (30), or albumin with PSI and CURB-65 (31). 
In our sample, NT-ProBNP improves the prognostic capacity of all 
three scales. It improves PSI by 3% and CURB-65 by 4%. It is important 
to note the predictive improvement of the ATS/IDSA scale improved 
by 11% when associated with NT-ProBNP, reaching an AUC of 93% 
with a correct classification of 91%. The results in this regard are dis-
similar in different studies. When Jeong et al. associated NT-ProBNP 
with PSI and CURB-65, they found no statistically significant improve-
ment; nor did Lin et al. find an improvement in critical patients when 
associating NT-ProBNP with the ATS/IDSA scale, although there was 
an improvement when NT-ProBNP was associated with the APACHE II 
scale (4, 7). Therefore, this subject is still open to debate.
c. Assess improved outcome prediction by associating 
NT-ProBNP and other biomarkers
To our knowledge, there is no study using the assessment of di-
agnostic tests to improve the predictive of a prognosis of mortality 
by combining NT-ProBNP with another biomarker.
In our study, NT-ProBNP improves the diagnostic performance 
of classic inflammatory-infectious biomarkers by 24% for CRP and 
19% for PCT. It is worthy of note that the PCT model together with 
NT-ProBNP reaches an AUC of 85%, greater than the AUC provided 
for PSI (15, 16). Furthermore, in this sample, these two biomarkers 
had a specificity of 98% in detecting mortality at 30 days, an extreme-
ly valuable combination for detecting high risk patients. 
d. Assess improved prediction of outcome by associating 
NT-ProBNP with predictive scales and biomarkers
A study of predictive improvement by associating predictive 
scales with NT-ProBNP has already been analyzed, with inconsis-
tent results. Jeong et al. did not find that NT-ProBNP improved PSI, 
CURB-65, or APACHE II (4). Lin et al. (7) did not find that association of 
NT-ProBNP with minor ATS/IDSA 2007 criteria improved these predic-
tions, although it did do so with APACHE II.
Nowak et al. (5) considered that associating NT-ProBNP with 
the categorical value of PSI provided additional information. They 
observed that NT-ProBNP helps detect high or intermediate risk pa-
tients when PSI alone marked them as high risk.
In our sample, of all the logistic regression models proposed 
that included age together with biomarkers and predictive scales, 
the simplest and most profitable variant would be to use the ATS/
IDSA scale and NT-ProBNP, which would give a sensitivity of 80%, a 
specificity of 92%, good classification of 91% of patients, and an AUC 
of 93%. That is, in our study, NT-ProBNP combined with the ATS/IDSA 
2007 scale is the best combination between biomarkers and predic-
tive scales for detecting severe CAP.
Survival analysis
In the case of CAP, mortality is concentrated within the first few 
days, with 20% of patients dying in the first 48 h and 50% within the 
first week. Corrales-Medina et al. (32) detected the majority of car-
diovascular complications in the first week. As these complications 
have a very early onset, the patient may be in the emergency room, 
observation area, or short stay ward, thus reasserting the importance 
of early diagnosis and treatment in the HER but also the need for 
tools that help predict mortality. In our study, survival analysis also 
revealed that 20% of patients die within the first 48 h and 50% within 
the first 5 days. Apart from the patients that died, those with NT-ProB-
NP values above the 1.769 ng/L cutoff point showed statistically sig-
nificant differences in survival time compared to those that died with 
values below the cutoff point (Figure 3).
Study limitations
The limitations are basically those derived from a single-center 
followup study. This study did not include patients with suspected 
CAP treated in primary healthcare without being referred to the hos-
pital for assessment. 
No analytical controls of NT-ProBNP or any other biomarker were 
performed during the month of followup, thus limiting our conclu-
sions to assess the evolutionary prognostic capacity. Although we 
analyzed eight biomarkers, the sample numbers were low for lactate, 
high-sensitivity troponin T, and D-dimer.
Conclusion
In our sample, elevation of NT-ProBNP at the time of diagnosis 
in the emergency room was associated with increased short term 
mortality. This biomarker could be an independent risk factor to 
predict this mortality. These findings are in agreement with current 
literature; NT-ProBNP is a prognosis tool that has begun to appear 
in review articles as an emerging biomarker (33). Until its individual 
prognostic value is confirmed, this marker could be useful in the ini-
tial assessment of CAP patients and be included as a tool in addition 
to predictive scales; also, it could perhaps be used in the future to 
design individual treatment strategies. 
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